301 A novel biomarker for early stage ovarian cancer, and a new target for immunotherapy? | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

E-Poster viewings

Ovarian Cancer

IGCS19-0367

301 A novel biomarker for early stage ovarian cancer, and a new target for immunotherapy?

Free

Authors

G Khan 1University of Hull, Department of Biomedical Sciences, Hull, UK PubMed articles Google scholar articles
K Grayson 1University of Hull, Department of Biomedical Sciences, Hull, UK PubMed articles Google scholar articles
S Brooks 2Southampton University Hospitals Trust, Biomedical Imaging Unit, Southampton, UK PubMed articles Google scholar articles
K Mills 3Queens’ University Belfast, Centre for Cancer Research and Cell Biology, Belfast, UK PubMed articles Google scholar articles
B Guinn 1University of Hull, Department of Biomedical Sciences, Hull, UK PubMed articles Google scholar articles

Citation

Khan G, Grayson K, Brooks S, et al

301 A novel biomarker for early stage ovarian cancer, and a new target for immunotherapy?

International Journal of Gynecologic Cancer 2019;29:A126.

Publication history

First published September 18, 2019.

Online issue publication

September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.